Navigation Links
Aegera Therapeutics Initiates A Randomized Phase 2 Combination Study of AEG35156 for 1st Line Treatment of Non-Small Cell Lung Cancer
Date:1/8/2009

ncer cells acquire multiple mutations that disable their normal response to apoptotic triggers. AEG35156, a second generation antisense which targets XIAP, is designed to lower the apoptotic threshold of cancer cells, enhancing their sensitivity to intrinsic death and chemotherapy, without harming healthy cells. Aegera's published data with AEG35156, both in vitro and in vivo, strongly supports this hypothesis, and validates XIAP as a novel drug target for the development of anti-cancer therapeutics.

About Aegera Therapeutics Inc.

Aegera Therapeutics is a clinical stage biotechnology company focused on developing novel targeted therapies that address major unmet medical needs. In addition to AEG35156, Aegera has two additional programs in clinical development for the treatment of cancer and neuropathic pain. Details of these programs can be found on Aegera's website at www.aegera.com.


'/>"/>
SOURCE AEGERA THERAPEUTICS INC.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Aegera Therapeutics phase 1/2 clinical trial results selected for oral presentation at 2008 ASH Annual Meeting
2. Aegera Therapeutics collaboration with Human Genome Sciences leads to the initiation of a Phase 1 clinical trial with lead IAP inhibitor HGS1029 and receipt of first milestone payment
3. Aegera Therapeutics welcomes two experienced executives to its board of directors
4. Aegera initiates Phase 1 clinical trial of AEG33773 - A small molecule in development for diabetic neuropathic pain
5. Human Genome Sciences and Aegera Therapeutics Announce Licensing and Collaboration Agreement on Novel Anti-Cancer Drugs
6. Amicus Therapeutics Adds Sol J. Barer, Ph.D. to Board of Directors
7. Cell Therapeutics Announces Receipt of NASDAQ Panel Decision to Transfer to NASDAQ Capital Market
8. Horizon Therapeutics Announces Senior Management Appointments
9. Nektar Therapeutics President and CEO, Howard W. Robin, to Present at the 27th Annual J.P. Morgan Healthcare Conference in San Francisco
10. Orexigen(R) Therapeutics Issued a Key Fourth U.S. Patent on Contrave(R)
11. Cornerstone Therapeutics Provides Update on Integration Activities and Issues 2008 Revenue Guidance
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... In recent years, growing suspicion about the pharmaceutical ... and promotion has led to unprecedented levels of public ... about the insidious impact of commercialization of research, has ... the world’s biggest pharmas for illegal marketing activities, allegations ...
(Date:1/14/2014)... MD (PRWEB) January 14, 2014 ... to developing innovative information technology solutions for patients, ... health care stakeholders, announced today the signing of ... US Food and Drug Administration (FDA). This ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors contributed ... In this time period, doctors did not know that they ... the death of vulnerable patients. In the same way, medical ... be unwittingly transmitting herpes viruses to their patients. The CBCD ...
Breaking Biology Technology:The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... , , PASADENA, Calif., July ... ), Landlord of Choice to the Life Science Industry(R), announced today ... Lilly and Company as the anchor tenant at the Alexandria Center ... Center"). Lilly has leased approximately 91,000 rentable square feet, as ...
... BEIJING, July 22 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. ... in China, today announced that it has,initiated dosing today in ... A (H1N1). Results are expected in September,2009. , ... split viron,vaccine with adjuvant, and whole viron vaccine with adjuvant, ...
... , CHICAGO, July 22 Research presented at ... indicates that monitoring cardiac transplant patients with the Urine NGAL ... monitor cyclosporine-induced toxicity and adjust doses of cyclosporine drugs to ... , In a scientific poster presented at ...
Cached Biology Technology:Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 2Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 3Alexandria Real Estate Equities, Inc. Signs Biopharmaceutical Company, Lilly, as Anchor New York City Tenant at the Alexandria Center for Science and Technology 4Sinovac Initiates Dosing in Human Clinical Trial of Panflu for Pandemic Influenza A (H1N1) 2Investigational Urine NGAL Biomarker Shows Promise to Monitor Cyclosporine Toxicity in Cardiac Transplant Patients 2
(Date:4/17/2014)... 2014The development of stem cell therapies to cure a ... stem cell populations based on cell surface markers. Researchers ... marker that is highly expressed in a type of ... they describe in an article in BioResearch Open ... Inc., publishers. The article is available free on the ...
(Date:4/17/2014)... consumption advisories for expecting mothers are ineffective in ... organic pollutants (POPs). , The study, performed ... Toronto Scarborough PhD student Matt Binnington and Professor ... environmental contamination, a mother,s compliance with advisories, and ... exposure in her children. , Their model estimates ...
(Date:4/17/2014)... A credit-card-sized anthrax detection cartridge developed at Sandia National ... testing safer, easier, faster and cheaper. , ... commonly found in soils all over the world and ... humans and animals. The bacteria can survive in harsh ... anthracis may occur through skin contact, inhalation of ...
Breaking Biology News(10 mins):Fish consumption advisories fail to cover all types of contaminants 2Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... German . , Wounds suffered by ... to work, the patient,s physician must discuss the situation ... best approach. However, e-mailing the files containing the diagnosis ... process. Telemedicine could facilitate communication and provide a better ...
... Matthew Levy, Ph.D., assistant professor of biochemistry at Albert ... awarded more than $700,000 by Stand Up To Cancer ... will focus on creating self-guiding drugs that target only ... unpleasant side effects of current therapies. Dr. Levy is ...
... exhaustive research into venom produced by snakes and spiders, ... a mystery. Now, a study of 158 catfish species, ... Biology , has catalogued the presence of venom glands ... Wright, from the University of Michigan, USA, carried out ...
Cached Biology News:A virtual physician's conference 2Einstein receives high-risk/high-reward cancer research funding 2Einstein receives high-risk/high-reward cancer research funding 3
... net results - with a modular approach ... management! The ChemStation Plus NDS family provides ... acquisition and data management, giving you the ... your labs needs now and that can ...
... Best: DASGIPs Process Control integrates Process ... comprehensive documentation for cultivation processes. A ... pH, dissolved oxygen, temperature and agitation ... Profiles, e.g. constant or scheduled media ...
... for immunological studies, vaccine development, and ... and powerful Paraflo microfluidic on-chip synthesis ... part of our comprehensive Epitope Peptide ... Content Probe content is completely ...
... These extended-length microarrays are custom designed ... format configurations are available: 8,455 features per ... or 22,575 features per array (1 array/slide). ... oligonucleotide probe length - This extended ...
Biology Products: